PRA International expanded its Asia-Pacific operations into New Zealand, hiring staff there and establishing a legal entity. The New Zealand staff will work closely with PRA’s office in Sydney, Australia. New Zealand is a key research location for studies in skin cancer, multiple sclerosis, and asthma, the CRO said. The country is known for high recruitment rates, an efficient regulatory environment and counter seasonality—which is advantageous to influenza and allergy studies.

"We are very pleased with the expansion to New Zealand," noted Edward Ian, PRA's Senior Director of Operations for Asia-Pacific.  "It continues our expansion in this critical region and is an ideal complement to our operations in Australia."